Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab

NCT00308581 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00308581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00308581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2006
Completion date
April 30, 2008
Enrollment
539 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease